OM Pharma
11/2/2022
Implementation of a purchase price allocation and development of an impairment model
Healthcare
Valuation & Financial Modeling
OM Pharma was integrated into the Galenica Group in 2009. As a part of Vifor Pharma it was separated from Galenica in 2017 and acquired by a Swiss group, Optimus Holding Ltd, in 2020. According to IFRS, a Purchase Price Allocation (PPA) had to be performed after the transaction was completed. IFBC was engaged with the implementation of the PPA as well as the development of a standardized impairment model.
Founded in 1937 in Geneva, OM Pharma is a globally positioned biopharmaceutical company.
Back